Clinical Trial

Liraglutide Effect in Atrial Fibrillation

Study acronym: LEAF

Active, Not Recruiting Phase 4

Summary

The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady) the activity between the fat deposits surrounding the heart and the left atrium. To reduce the amount of EAT, this study will use a medication called Liraglutide. This medication is known to work on fat deposits and produce weight loss. The investigator is conducting this study to find out if Liraglutide will reduce the fat deposits surrounding the participant's heart, and stabilize (and perhaps reduce or eliminate) atrial fibrillation activity.

Protocol Amendment History 11 amendments

This ClinicalTrials.gov record has been amended 11 times since 2019-02-26; most recent amendment 2026-04-27.

Status change: Recruiting → Active, Not Recruiting 2023-04-18

Trial Details

NCT Number	NCT03856632
Lead Sponsor	University of Miami
Conditions	Atrial Fibrillation
Enrollment	60 participants
Start Date	2019-03-18
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-01